Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4,991 INR | -2.00% | -4.23% | -3.95% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company returns high margins, thereby supporting business profitability.
- The company is in a robust financial situation considering its net cash and margin position.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- With an expected P/E ratio at 33.26 and 28.41 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's enterprise value to sales, at 4.57 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.95% | 7.3B | C- | ||
+55.19% | 815B | C+ | ||
+45.45% | 654B | B | ||
-6.09% | 354B | C+ | ||
+21.92% | 337B | B- | ||
+19.51% | 247B | B+ | ||
+3.44% | 229B | A+ | ||
+13.97% | 219B | B- | ||
+10.86% | 171B | C+ | ||
-2.78% | 159B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ALKEM Stock
- Ratings Alkem Laboratories Limited